Neurocrine Biosciences Inc
NBIXHealthcare|Drug Manufacturers - Specialty & Generic|USA
$177.19
-3.48 (-1.93%)
DCF (FCF)
$85.65
Tangible Book
$33.88
Graham Number
$70.17
Earnings Power
$56.09
Upcoming Data Readouts (15)
Jan 2027
Est. completion
P4Schizophrenia
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
NCT07105111n=50
Feb 2027
Est. completion
P2Tardive Dyskinesia
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
NCT07365462n=100
Feb 2027
Est. completion
P2Trichotillomania (Hair-Pulling Disorder)
Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults
NCT05207085n=20
Jul 2027
Est. completion
P3Major Depressive Disorder
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112n=200
Jul 2027
Est. completion
P3Major Depressive Disorder
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06963021n=200
Jul 2027
Est. completion
P3Major Depressive Disorder
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624n=200
Aug 2027
Est. completion
Oct 2027
Est. completion
P3Schizophrenia
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT06963034n=284
Nov 2027
Est. completion
P3Schizophrenia
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
NCT07105098n=284
Feb 2028
Est. completion
P2Bipolar I Disorder
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
NCT07288320n=150
Jul 2028
Est. completion
P3Major Depressive Disorder
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT07196501n=550
May 2029
Est. completion
P3Major Depressive Disorder
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401n=850
Jul 2029
Est. completion
P3Schizophrenia
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
NCT07227818n=560
Sep 2029
Est. completion
P2Congenital Adrenal Hyperplasia
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
NCT07187375n=7
Dec 2031
Est. completion
P3Schizophrenia
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
NCT07114874n=600
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Jul 2023
P3
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
NCT04490915Mar 2023
P3
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
NCT04806451